Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)

(2017) M.J. Duffy et al.   EUROPEAN JOURNAL OF CANCER

High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast

(2016) Eun Young Kim et al.   Journal of Breast Cancer

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) E. Senkus et al.   ANNALS OF ONCOLOGY

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

(2013) N. Harbeck et al.   EUROPEAN JOURNAL OF CANCER

High levels of uPA and PAI-1 predict a good response to anthracyclines

(2009) Simona Borstnar et al.   BREAST CANCER RESEARCH AND TREATMENT

Plasminogen activator inhibitor-1: The double-edged sword in apoptosis

(2008) Rashna D. Balsara et al.   THROMBOSIS AND HAEMOSTASIS